Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Historical review of 1980s thrombolytic advances leaves open whether next-generation agents will improve contemporary outcomes; prospective trials needed.
A FIBRIN thrombus impedes blood flow in an artery or a vein, subsequent events partly depend on the fate of the thrombus, which may fragment and embolize, undergo organization, or lyse. There is deceivingly sketchy information on the first two processes. However, knowledge of the intricate system of physiological fibrinolysis is rapidly growing and, as a result, a new generation of thrombolytic drugs is being developed.
No takes yet. Share an insight, caveat, or question.
Verstraete et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: